PD-1 drugs for Hepatocellular Carcinoma
5 tracked PD-1 drugs in the Hepatocellular Carcinoma race. The class explanation lives on the PD-1 page; the full indication pipeline across every mechanism is on the Hepatocellular Carcinoma page.
3 approved / phase 42 Phase 3
Head-to-head evidence: Camrelizumab vs Nivolumab · Camrelizumab vs Pembrolizumab · Nivolumab vs Opdivo Qvantig · Nivolumab vs Pembrolizumab · Nivolumab vs Penpulimab · Opdivo Qvantig vs Pembrolizumab